πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 376 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8334373

Nuclease resistant double-stranded ribonucleic acid

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8324366

Compositions and methods for delivering RNAI using lipoproteins

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8324368

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8318693

Compositions and methods for inhibiting expression of mutant EGFR gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8293719

iRNA agents targeting VEGF

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8288525

Compositions and methods for inhibiting expression of CD45 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 16 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 11 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8273868

Compositions and methods for inhibiting viral replication

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8273870

Compositions and methods for inhibiting expression of a mutant gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8273869

Lipid formulated dsRNA targeting the PCSK9 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 25 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8268799

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8263572

RNAi modulation of RSV and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8227188

Enhancement of influenza gene expression

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8222222

Compositions and methods for inhibiting expression of the PCSK9 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8202980

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 19 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8188061

RNAi modulation of APOB and uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8183362

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8168776

Method for making a 21 nucleotide double stranded RNA chemically linked at one end

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8168775

Compositions and methods for inhibiting expression of transthyretin

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8163711

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8158773

RNAi modulation of RSV and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8158601

Lipid formulation

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8148344

Compositions and methods for mediating RNAi in vivo

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8143390

Compositions and methods for inhibiting expression of anti-apoptotic genes

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8119608

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted